GeneDx (WGS) Expected to Announce Quarterly Earnings on Monday

GeneDx (NASDAQ:WGS) is expected to be announcing its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect GeneDx to post earnings of $0.11 per share and revenue of $120.80 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 8:30 AM ET.

GeneDx Stock Performance

Shares of WGS opened at $90.15 on Monday. The firm has a market capitalization of $2.61 billion, a P/E ratio of 1,001.67 and a beta of 2.01. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. GeneDx has a one year low of $55.17 and a one year high of $170.87. The business has a fifty day moving average of $119.20 and a 200 day moving average of $125.33.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Canaccord Genuity Group upped their price target on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. BTIG Research increased their price objective on shares of GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a report on Friday, December 12th. Wells Fargo & Company upgraded shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price objective on the stock in a research report on Monday, February 9th. Finally, Wall Street Zen downgraded shares of GeneDx from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, GeneDx currently has an average rating of “Moderate Buy” and a consensus price target of $138.13.

Insider Buying and Selling at GeneDx

In other news, CFO Kevin Feeley sold 3,855 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $143.87, for a total value of $554,618.85. Following the completion of the sale, the chief financial officer owned 8,731 shares in the company, valued at approximately $1,256,128.97. The trade was a 30.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Joshua Ruch sold 38,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $160.37, for a total transaction of $6,094,060.00. Following the completion of the transaction, the director directly owned 11,941 shares of the company’s stock, valued at $1,914,978.17. This trade represents a 76.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 68,961 shares of company stock valued at $10,027,891. Corporate insiders own 29.60% of the company’s stock.

Institutional Trading of GeneDx

Large investors have recently bought and sold shares of the stock. Cerity Partners LLC raised its position in GeneDx by 6.0% during the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after acquiring an additional 142 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of GeneDx by 5.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after purchasing an additional 181 shares during the period. Kestra Advisory Services LLC purchased a new position in shares of GeneDx during the 4th quarter valued at approximately $27,000. Quarry LP lifted its stake in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the period. Finally, Greenline Wealth Management LLC acquired a new position in shares of GeneDx in the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.